

# 2023-5-5 Executive Team Meeting Notes

## Date

05 May 2023

## Attendees

Committee Member	Present	Absent
<a href="#">Kuffel, Gina (NIH/NCI) [C]</a>	X	
<a href="#">Unknown User (leblancak)</a>		X
<a href="#">Otridge, John (NIH/NCI) [C]</a>		X
<a href="#">Kim, Erika (NIH/NCI) [E]</a>	X	
<a href="#">Sommers, Connie (NIH/NCI) [E]</a>	X	
Debbie Knapp	X	
Toby Hecht	X	
<a href="#">Unknown User (parchmentr)</a>	X	

## Goals

- Discuss updates to ICDC and define emerging strategies and priorities

## SharePoint Site

<https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups>

## Outstanding Action Items

## Agenda

Item	Who	Talking Points
------	-----	----------------

DGAB Updates	<a href="#">Kuffel, Gina (NIH/NCI) [C]</a>	<p>Recently Released</p> <ul style="list-style-type: none"> <li>• <b>UC01</b> <ul style="list-style-type: none"> <li>◦ "Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation"</li> <li>◦ North Carolina State University</li> <li>◦ 36 cases, 73 files (1.54 TB)</li> <li>◦ Status: Released on 4/13/23</li> </ul> </li> </ul> <p>ICDC Studies in Active Submission</p> <ul style="list-style-type: none"> <li>• <b>ORGANOIDS01</b> <ul style="list-style-type: none"> <li>◦ Approved by SAC on 9/22/22</li> <li>◦ "Characterization of healthy and diseased canine tissues and organoids"</li> <li>◦ Iowa State University</li> <li>◦ Status: Submitters generating template-based loading files and uploading to S3 and Sharepoint</li> </ul> </li> <li>• <b>OSA03</b> <ul style="list-style-type: none"> <li>◦ Approved by SAC on 4/19/21</li> <li>◦ "Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma"</li> <li>◦ University of Minnesota</li> <li>◦ 44 cases</li> <li>◦ Status: Indexing of files is in progress by the DCF team, metadata has been loaded into the ICDC Dev tier</li> </ul> </li> </ul> <p>Additional Data Work</p> <ul style="list-style-type: none"> <li>• <b>GLIOMA01</b> <ul style="list-style-type: none"> <li>◦ Submitted metadata and files for 87 histopathology images currently in the TCIA to the Imaging Data Commons so we can access this data through an API.</li> </ul> </li> </ul>
BPSC Updates	<a href="#">Kuffel, Gina (NIH/NCI) [C]</a>	<ul style="list-style-type: none"> <li>• <a href="#">2022 BPSC Review Article</a> <ul style="list-style-type: none"> <li>◦ Cheryl spoke with Doug Thamm, editor of Veterinary and Comparative Oncology which has an impact factor and is open access and he said they would take it</li> </ul> </li> </ul>
Upcoming Steering Committee Meeting	<a href="#">Unknown User (parchmentr)</a>	<ul style="list-style-type: none"> <li>• Thursday May 18th</li> <li>• Proposed Agenda:</li> </ul>
Next Software Release	<a href="#">Kuffel, Gina (NIH/NCI) [C]</a>	<ul style="list-style-type: none"> <li>• Target date is June 20, 2023</li> <li>• New Features <ul style="list-style-type: none"> <li>◦ 2 new tabs on the Study Details page, one for supporting data and the other for clinical data observations</li> <li>◦ Full-text search for JBrowse</li> <li>◦ Liftover tracks for gene annotations from human hg38 to canFam genomes</li> <li>◦ Updated UI design for "My Files" page</li> <li>◦ Button for exporting a file manifest directly to the CGC</li> </ul> </li> </ul>

## Minutes (Not Verbatim)

RP - There is an internal NCI deadline to have new TOs submitted to contracting office.

## Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
  1. Search for conserved mutations between canine and human tumors
  2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
  5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

## Previous Meeting Minutes (Not Verbatim)

TH - Look at drug responses and the tumor itself to determine if there is a biomarker based on genomic expression. In the Intro of the BPSC paper, we could give examples of things that can be done based upon existing drug trial studies.

AL - In general, there is such a scarcity of credentialed biology in tumor progression. Drug mechanisms can be highlighted with an imaging reporter.

DK - Pre and post biopsies were attempted in Vemurafenib trial

AL - Until we have DBs to refer to and a more stable reference genome it is difficult to make progress.

## Action items